Zobrazeno 1 - 10
of 145
pro vyhledávání: ''
Autor:
Seock-Ah Im, Patrick Neven, John Crown, Rosa-Maria Espadero, Noelia Martínez, Yen-Shen Lu, Jonas Bergh, Thomas Bogenrieder, J. Alejandro Pérez-Fidalgo, Peter Schmid, Guy Jerusalem, Laura Schlieker, Serafin Morales, Dennis Chin-Lun Huang, Douglas Adamson, Javier Cortes, Anthony Gonçalves, Keun Seok Lee, Marie-Paule Sablin, Aleix Prat
Publikováno v:
Breast Cancer Research
Breast Cancer Research, 2021, 23 (1), pp.8. ⟨10.1186/s13058-020-01382-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research : BCR
Scientia
Breast Cancer Research, 2021, 23 (1), pp.8. ⟨10.1186/s13058-020-01382-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Breast Cancer Research : BCR
Scientia
Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus everolimus a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3fb312f1fe2cc964111c140ba48f774
https://hal.science/hal-03630009
https://hal.science/hal-03630009
Autor:
Jérôme Bourgeais, Christophe Olivier, Marie C. Béné, Emmanuel Gyan, Amélie Foucault, Sophie Hamard, Nicolas Vallet, Nathalie Gallay, Joevin Besombes, Laetitia Babin, François M. Vallette, Noémie Ravalet, Jorge Domenech, Olivier Herault, Frederic Picou, Pascal Loyer, Julien Lejeune
Publikováno v:
Cancers
Cancers, MDPI, 2021, 13 (22), pp.5699. ⟨10.3390/cancers13225699⟩
Volume 13
Issue 22
Cancers, Vol 13, Iss 5699, p 5699 (2021)
Cancers, 2021, 13 (22), pp.5699. ⟨10.3390/cancers13225699⟩
Cancers, MDPI, 2021, 13 (22), pp.5699. ⟨10.3390/cancers13225699⟩
Volume 13
Issue 22
Cancers, Vol 13, Iss 5699, p 5699 (2021)
Cancers, 2021, 13 (22), pp.5699. ⟨10.3390/cancers13225699⟩
Simple Summary Pesticide exposure is a public health concern. Two recent studies reported that exposure of normal primary bone marrow mesenchymal stem/stromal cells (BM-MSCs) to low-dose pesticide mixture induces deleterious consequences, such as oxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ed45b22cd64d390cd5052dd1b71ca9
https://hal.archives-ouvertes.fr/hal-03468294/file/cancers-13-05699-v2.pdf
https://hal.archives-ouvertes.fr/hal-03468294/file/cancers-13-05699-v2.pdf
Autor:
Constantine S. Tam, Christian Buske, Albert Oriol, Jeffrey Matous, Meletios A. Dimopoulos, Eva M. Briso, Shuo Ma, Israel Arango-Hisijara, Steven P. Treon, Jerry Ping, David MacDonald, Olivier Tournilhac, Judith Trotman, Alessandra Tedeschi
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (21), pp.5793-5800. ⟨10.1158/1078-0432.CCR-21-1497⟩
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (21), pp.5793-5800. ⟨10.1158/1078-0432.CCR-21-1497⟩
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Purpose: The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Wald
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441a6333f9c15b27126770402368aa0d
https://hal.uca.fr/hal-03440467
https://hal.uca.fr/hal-03440467
Autor:
Laura Streit, Didier Mutter, Sylvain Hugel, Sophie Moog, Stéphanie Lacomme, Virginie Andry, Claire Nomine-Criqui, Nicolas Vitale, Marion Rame, Michel Vix, Herbert A. Schmid, Stéphane Ory, Stéphane Gasman, Emeline Tanguy, Yannick Goumon, Laurent Brunaud, Florence Bihain, Sandra Lomazzi
Publikováno v:
Cancer Letters
Cancer Letters, Elsevier, 2021, ⟨10.1016/j.canlet.2021.10.009⟩
Cancer Letters, Elsevier, 2021, ⟨10.1016/j.canlet.2021.10.009⟩
International audience; Increasingly common, neuroendocrine tumors (NETs) are regarded nowadays as neoplasms potentially causing debilitating symptoms and life-threatening medical conditions. Pheochromocytoma is a NET that develops from chromaffin ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c27f013e0d2933b61bbbc888282398d
https://hal.archives-ouvertes.fr/hal-03389020/file/1-s2.0-S030438352100519X-main.pdf
https://hal.archives-ouvertes.fr/hal-03389020/file/1-s2.0-S030438352100519X-main.pdf
Autor:
Mohamed N. Triba, Adrien Rossary, Serge Hercberg, Aicha Demidem, L. Lécuyer, Pilar Galan, Philippe Savarin, Xinyu Liu, Tony Lionel Palama, Mathilde Touvier, Mélanie Deschasaux-Tanguy, Guowang Xu, Marie-Paule Vasson, Zhicheng Liu, Xiangping Lin
Publikováno v:
Cancers
Cancers, 2021, 13 (13), pp.3140. ⟨10.3390/cancers13133140⟩
Volume 13
Issue 13
Cancers, MDPI, 2021, 13 (13), pp.3140. ⟨10.3390/cancers13133140⟩
Cancers, Vol 13, Iss 3140, p 3140 (2021)
Cancers, 2021, 13 (13), pp.3140. ⟨10.3390/cancers13133140⟩
Volume 13
Issue 13
Cancers, MDPI, 2021, 13 (13), pp.3140. ⟨10.3390/cancers13133140⟩
Cancers, Vol 13, Iss 3140, p 3140 (2021)
Background: The prevention and early screening of PCa is highly dependent on the identification of new biomarkers. In this study, we investigated whether plasma metabolic profiles from healthy males provide novel early biomarkers associated with futu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70416e0fec66bdb2e2dc1e84b2b0ac5
https://hal.inrae.fr/hal-03316278/document
https://hal.inrae.fr/hal-03316278/document
Autor:
Pierre Laurent-Puig, H. Janicot, Charles Ricordel, Hélène Blons, Alexandra Langlais, Laurent Greillier, Philippe Fraisse, Marie Wislez, Isabelle Monnet, Nathalie Rabbe, Alain Makinson, Clarisse Audigier-Valette, Jean Philippe Spano, Elodie Amour, Julien Mazieres, Charlotte Domblides, Jacques Cadranel, Xavier Quantin, Armelle Lavolé, Lize Kiakouama-Maleka
Publikováno v:
Lung Cancer
Lung Cancer, 2021, 157, pp.124-130. ⟨10.1016/j.lungcan.2021.05.013⟩
Lung Cancer, 2021, 157, pp.124-130. ⟨10.1016/j.lungcan.2021.05.013⟩
International audience; IntroductionHIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::388ec124d0e3a9e85331be7209356ea0
https://inria.hal.science/hal-03526372
https://inria.hal.science/hal-03526372
Publikováno v:
OncoTargets and Therapy
OncoTargets and Therapy, Dove Medical Press, 2021, Volume14, pp.3949-3958. ⟨10.2147/ott.s312889⟩
OncoTargets and therapy
OncoTargets and Therapy, Dove Medical Press, 2021, Volume14, pp.3949-3958. ⟨10.2147/ott.s312889⟩
OncoTargets and therapy
Brice Leyrat,1,2 Xavier Durando,1â 5 Hugo Veyssiere,3â 5 Maureen Bernadach1,3â 5 1Département dâOncologie Médicale, Centre Jean Perrin, Clermont-Ferrand, 63011, France; 2Université Clermont Auvergne, UFR Médecine, Cler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b7122935b2a39ef625b42e318e07459
https://hal.archives-ouvertes.fr/hal-03294091/file/ott-14-3949.pdf
https://hal.archives-ouvertes.fr/hal-03294091/file/ott-14-3949.pdf
Autor:
Juliette Reure, Thomas Chevalier, Charlotte Dupuis, Florence Huguet, Amaury Daste, Christophe Le Tourneau, Tiphaine Lambert, Anderson Loundou, C. Toullec, Marc Alfonsi, Frederic Peyrade, Florent Peyraud, Nicolas Fakhry, Esmaa Saada-Bouzid, Jérôme Fayette, Sébastien Salas
Publikováno v:
Cancer Medicine
Cancer Medicine, Wiley, 2021, ⟨10.1002/cam4.3953⟩
Cancer Medicine, Vol 10, Iss 12, Pp 3952-3963 (2021)
Cancer Medicine, 2021, ⟨10.1002/cam4.3953⟩
Cancer Medicine, Wiley, 2021, ⟨10.1002/cam4.3953⟩
Cancer Medicine, Vol 10, Iss 12, Pp 3952-3963 (2021)
Cancer Medicine, 2021, ⟨10.1002/cam4.3953⟩
BACKGROUND Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients’ outcomes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c71adc9708f37d6e497d3e601c944d2
https://hal.sorbonne-universite.fr/hal-03242636/file/cam4.3953.pdf
https://hal.sorbonne-universite.fr/hal-03242636/file/cam4.3953.pdf
Autor:
Loic Mourey, Christophe Massard, Remy Delva, Joseph Ciccolini, Fabienne Thomas, Christine Chevreau, Thomas Filleron, Jean-Pierre Lotz, Stéphane Culine, Gwenaelle Gravis, Marine Gross-Goupil, Etienne Chatelut, Aude Flechon, Angelo Paci, Jacques-Olivier Bay, Jérôme Guitton, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Bénédicte Lelièvre, Karim Fizazi
Publikováno v:
Cancer Medicine
Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
Background High‐dose chemotherapy (HDCT) with TI‐CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug monitoring of carboplatin for optimizing area under the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4da192febd5a6e0225a744c30d9760
https://hal.univ-angers.fr/hal-03208728
https://hal.univ-angers.fr/hal-03208728
Autor:
Vassiliki Karantza, Kenji Tamura, Xuan Zhou, Eric P. Winer, Seock-Ah Im, Jaime Mejia, Isabell Witzel, Nadia Harbeck, A. Gonçalves, Rebecca Dent, Stefania Zambelli, Laura Testa, Peter Schmid, Shoichiro Ohtani, Keun Seok Lee, Oleg Lipatov, Javier Cortes, Nicholas C. Turner, Eva Muñoz-Couselo, Fabrice Andre
Publikováno v:
Lancet Oncology
Lancet Oncology, 2021, 22 (4), pp.499-511. ⟨10.1016/S1470-2045(20)30754-3⟩
Lancet Oncology, 2021, 22 (4), pp.499-511. ⟨10.1016/S1470-2045(20)30754-3⟩
Pembrolizumab showed durable antitumour activity and manageable safety in metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 trials. In this study, we compared pembrolizumab with chemotherapy for second-line or thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49802cd31756dcf686cf9480c3f647ac
https://hal.science/hal-03629997
https://hal.science/hal-03629997